Tapentadol (Nucynta)--a new analgesic.
The FDA has approved tapentadol hydrochloride (Nucynta--Ortho-McNeil Janssen) for oral treatment of moderate to severe acute pain in patients >18 years old. It has been classified as a Schedule II controlled substance. Tapentadol (Nucynta) is a centrally acting oral analgesic with opioid and adrenergic activity. In studies published to date, it was as effective as oxycodone or morphine with a lower incidence of gastrointestinal adverse effects, but until more data become available, older analgesics are preferred.
D000700:Analgesics / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006801:Humans; D010146:Pain / Q000188:drug therapy*; D010636:Phenols / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000077432:Tapentadol
D000700:Analgesics; D010636:Phenols; D000077432:Tapentadol